Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Net Income (2024 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Net Income for 2 consecutive years, with -$15.1 million as the latest value for Q4 2025.

  • Quarterly Net Income fell 69.65% to -$15.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$55.5 million through Dec 2025, down 255.0% year-over-year, with the annual reading at -$55.5 million for FY2025, 255.0% down from the prior year.
  • Net Income hit -$15.1 million in Q4 2025 for Connect Biopharma Holdings, up from -$17.2 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $14.8 million in Q2 2024 to a low of -$17.2 million in Q3 2025.